Uniphar PLC (DE:0NR)
FRANKFURT:0NR
0NR Stock Chart & Stats
€3.74
-€0.05(-2.39%)
At close: 4:00 PM EST
€3.74
-€0.05(-2.39%)
Day’s Range― - ―
52-Week Range€3.24 - €4.93
Previous CloseN/A
Volume0.00
Average Volume (3M)34.00
Market Cap
€1.21B
Enterprise Value€1.35B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)24.3
Beta0.63
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding259,574,300
10 Day Avg. Volume93
30 Day Avg. Volume34
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Contracts And Client BasePharma Services secured 17 new EAP contracts, one of its best new contract years, and increased its client base to 10 of the top 20 big pharma.
Financial PerformanceUniphar delivered an impressive set of financial results in FY24, is on track for another strong year in FY25, has solidified its €200m EBITDA target by 2028, and is underscoring its confident outlook by launching a €35m share buy-back.
ValuationThe valuation remains undemanding at 7.0x EV/EBITDA and is still heavily discounted to peers, especially in light of the implied Asker valuation.
Bears Say
DebtNet debt is now modeled at around €250m, but this is expected to reduce upon successful execution of the previously flagged sale/leaseback of Uniphar's existing assets.
Stock PricingEven after a recent mini relief rally, the stock is seen as fundamentally mispriced, trading at just 6.5x 2025 EV/EBITDA, against a strong track record and organic growth prospects.
Uniphar PLC News
0NR FAQ
What was Uniphar PLC’s price range in the past 12 months?
Uniphar PLC lowest stock price was €3.23 and its highest was €4.93 in the past 12 months.
What is Uniphar PLC’s market cap?
Uniphar PLC’s market cap is €1.21B.
When is Uniphar PLC’s upcoming earnings report date?
Uniphar PLC’s upcoming earnings report date is Sep 02, 2026 which is in 72 days.
How were Uniphar PLC’s earnings last quarter?
Uniphar PLC released its earnings results on Feb 24, 2026. The company reported €0.172 earnings per share for the quarter, beating the consensus estimate of €0.142 by €0.03.
Is Uniphar PLC overvalued?
According to Wall Street analysts Uniphar PLC’s price is currently Overvalued.
Does Uniphar PLC pay dividends?
Uniphar PLC does not currently pay dividends.
What is Uniphar PLC’s EPS estimate?
Uniphar PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Uniphar PLC have?
Uniphar PLC has 259,574,300 shares outstanding.
What happened to Uniphar PLC’s price movement after its last earnings report?
Uniphar PLC reported an EPS of €0.172 in its last earnings report, beating expectations of €0.142. Following the earnings report the stock price went down -0.124%.
Which hedge fund is a major shareholder of Uniphar PLC?
Currently, no hedge funds are holding shares in DE:0NR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Uniphar PLC
Uniphar plc functions as a multifaceted healthcare solutions provider, serving markets across the Republic of Ireland, the United Kingdom, and various international territories. Its operations are segmented into three primary divisions: Commercial & Clinical, Product Access, and Supply Chain & Retail. The Commercial & Clinical division provides outsourced services encompassing sales, marketing, and integrated account management for pharmaceutical and medical device manufacturers, also managing the distribution and support for medical device producers. The Product Access division facilitates access to pharmaceutical and medical treatments through on-demand services, fostering vital connections between manufacturers and healthcare stakeholders; additionally, its exclusive access services establish tailored distribution agreements for crucial pharmaceutical brands. The Supply Chain & Retail division manages the pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals, and veterinary practices, and also oversees a network of retail pharmacies operating under the Life, Allcare, and Hickey's banners. Beyond its core divisional activities, Uniphar delivers a broad spectrum of specialized services, including pharmacy support, comprehensive pharmaceutical supply chain management, specialist nursing and infusion services, medical device distribution, and healthcare technology solutions. It further extends its expertise through data intelligence, consultancy, pharmaceutical advisory, and medical affairs services, alongside online pharmacy operations, product fostering, and data analytics for the pharmaceutical sector. Established in 1967, Uniphar plc maintains its headquarters in Dublin, Ireland.
Technical Analysis
Options Prices
Currently, No data available
---